Creatine for neuroprotection in neurodegenerative disease: end of story?
The DOI matches its Crossref record; 74 of the 74 references it cites were found in a registry or an index.
Abstract
Creatine (Cr) is a natural compound that plays an important role in cellular energy homeostasis. In addition, it ameliorates oxidative stress, glutamatergic excitotoxicity, and apoptosis in vitro as well as in vivo. Since these pathomechanisms are implicated to play a role in several neurodegenerative diseases, Cr supplementation as a neuroprotective strategy has received a lot of attention with several positive animal studies in models of Parkinson's disease (PD), Huntington's disease (HD), and amyotrophic lateral sclerosis (ALS). This has led to a number of randomized clinical trials (RCT) with oral Cr supplementation, with durations up to 5 years. In this paper, we review the evidence and consequences stemming from these trials. In the case of PD, the initial phase II RCT was promising and led to a large and well-designed phase III trial, which, however, turned out to be negative for all outcome measures. None of the RCTs that have examined effects of Cr in ALS patients showed any clinical benefit. In HD, Cr in high doses (up to 30 g/day) was shown to slow down brain atrophy in premanifest Huntingtin mutation carriers. In spite of this, proof is still lacking that Cr can also have beneficial clinical effects in this group of patients, who will go on to develop HD symptoms. Taken together, the use of Cr supplementation has so far proved disappointing in clinical studies with a number of symptomatic neurodegenerative diseases.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, there was some evidence that creatine supplementation slowed down progression of brain atrophy in patients with HD (although clinical markers were unaffected).”
From International Society of Sports Nutrition position stand: safety and efficacy of creatine supplementation in exercise, sport, and medicine (2017) · cites this paper as [23]
In the citing paper
“clinical populations may need to consume 10–30 g/day throughout their lifespan to offset creatine synthesis deficiencies and/or provide therapeutic benefit in various disease states”
From International Society of Sports Nutrition position stand: safety and efficacy of creatine supplementation in exercise, sport, and medicine (2017) · cites this paper as [23]
In the citing paper
“However, higher levels of creatine supplementation for longer periods of time may be needed to increase brain concentrations of creatine, offset creatine synthesis deficiencies, or influence disease states”
From International Society of Sports Nutrition position stand: safety and efficacy of creatine supplementation in exercise, sport, and medicine (2017) · cites this paper as [23]
In the citing paper
“Results revealed no clinical benefit on patient outcomes in patients with PD or ALS.”
From International Society of Sports Nutrition position stand: safety and efficacy of creatine supplementation in exercise, sport, and medicine (2017) · cites this paper as [23]
In the citing paper
“Nevertheless, these studies show that creatine supplementation has been used to treat children and adults with neurodegenerative conditions and is apparently safe and well-tolerated when taking up to 30 g/day for 5 years in these populations.”
From International Society of Sports Nutrition position stand: safety and efficacy of creatine supplementation in exercise, sport, and medicine (2017) · cites this paper as [23]
5 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Motor Neuron Degeneration in Mice that Express a Human Cu,Zn Superoxide Dismutase Mutation
Gurney, M. E., Pu, H., Chiu, A. Y., Dal Canto, M. C., Polchow, C. Y., Alexander, D. D., Caliendo, J., Hentati, A., Kwon, Y. W., Deng, H.-X., et al. (1994) · Science · doi:10.1126/science.8209258 · Cited by 4,143 · cited 1×
“These mice show early mitochondrial swelling and vacuolization as well as altered electron transport chain enzyme activities, corresponding to similar mitochondrial abnormalities observed in post-mortem spinal cords of ALS patients (Gurney et al. 1994; Wong et al. 1995; Hervias et al. 2006).”
BackgroundStages in the development of Parkinson’s disease-related pathology
Braak, H., Ghebremedhin, E., Rüb, U., Bratzke, H., & Del Tredici, K. (2004) · Cell and Tissue Research · doi:10.1007/s00441-004-0956-9 · Cited by 2,689 · cited 1×
“This prophylactic Cr loading seems unfeasible in the case of human neurodegenerative disease, where at symptom onset and time of diagnosis the neuropathological processes are believed to have been active for a long time (Braak et al. 2004).”
BackgroundWong, P. C., Pardo, C. A., Borchelt, D. R., Lee, M. K., Copeland, N. G., Jenkins, N. A., Sisodia, S. S., Cleveland, D. W., & Price, D. L. (1995) · Neuron · doi:10.1016/0896-6273(95)90259-7 · Cited by 1,445 · cited 1×
“These mice show early mitochondrial swelling and vacuolization as well as altered electron transport chain enzyme activities, corresponding to similar mitochondrial abnormalities observed in post-mortem spinal cords of ALS patients (Gurney et al. 1994; Wong et al. 1995; Hervias et al. 2006).”
BackgroundFrom charcot to lou gehrig: deciphering selective motor neuron death in als
Cleveland, D. W., & Rothstein, J. D. (2001) · Nature Reviews Neuroscience · doi:10.1038/35097565 · Cited by 1,389 · cited 18×
“For the case of Cr in ALS, data are also not encouraging.”
BackgroundInfluentialBeal, M., Brouillet, E., Jenkins, B., Ferrante, R., Kowall, N., Miller, J., Storey, E., Srivastava, R., Rosen, B., & Hyman, B. (1993) · The Journal of Neuroscience · doi:10.1523/jneurosci.13-10-04181.1993 · Cited by 1,027 · cited 1×
“Systemic administration of the respiratory chain complex II inhibitors 3-nitropropionic acid or malonate to rats leads to a behavioural and neuropathological phenotype resembling human HD (Beal et al. 1993).”
BackgroundMitochondria in the aetiology and pathogenesis of Parkinson's disease
Schapira, A. H. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70327-7 · Cited by 883 · cited 1×
“Even though its pathogenesis is far from understood, mitochondrial dysfunction and oxidative damage have been suggested to play a key role in PD (Schapira 2008).”
BackgroundThe creatine kinase system and pleiotropic effects of creatine
Wallimann, T., Tokarska-Schlattner, M., & Schlattner, U. (2011) · Amino Acids · doi:10.1007/s00726-011-0877-3 · Cited by 797 · cited 1×
“In combination with phosphocreatine (PCr) and the creatine kinases (CK), it serves as an efficient energy buffering and energy transportation system (Hemmer and Wallimann 1993; Wallimann et al. 2011).”
BackgroundNeuroprotective effects of creatine in a transgenic animal model of amyotrophic lateral sclerosis
Klivenyi, P., Ferrante, R. J., Matthews, R. T., Bogdanov, M. B., Klein, A. M., Andreassen, O. A., Mueller, G., Wermer, M., Kaddurah-Daouk, R., & Beal, M. F. (1999) · Nature Medicine · doi:10.1038/6568 · Cited by 682 · cited 1×
“Two Cr supplementation studies by the same group reported a dose-dependent increase in survival compared to placebo, reduction of neuronal cell death, as well as a delay of the motor phenotype, with 1–2 % of Cr, started within 1–2 months of animal age (Klivenyi et al. 1999; Andreassen et al. 2001b).”
BackgroundNeuroprotective Effects of Creatine in a Transgenic Mouse Model of Huntington's Disease
Ferrante, R. J., Andreassen, O. A., Jenkins, B. G., Dedeoglu, A., Kuemmerle, S., Kubilus, J. K., Kaddurah-Daouk, R., Hersch, S. M., & Beal, M. F. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-12-04389.2000 · Cited by 522 · cited 2×
“…with 30 g of Cr/day may also be reflected by the fact that in the typical mouse studies, brain Cr increased by 21 ± 3.8 % while in the human randomized trials, only increases between 7.5 and 13 % could be obtained (Ferrante et al. 2000; Atassi et al. 2010; Hersch et al. 2006; Lyoo et al. 2003).”
BackgroundInfluentialDesign, power, and interpretation of studies in the standard murine model of ALS
Scott, S., Kranz, J. E., Cole, J., Lincecum, J. M., Thompson, K., Kelly, N., Bostrom, A., Theodoss, J., Al‐Nakhala, B. M., Vieira, F. G., et al. (2008) · Amyotrophic Lateral Sclerosis · doi:10.1080/17482960701856300 · Cited by 504 · cited 3×
“They controlled for common methodological issues and confounders in animal studies, such as small animal numbers per group, lack of control for low transgene copy number, and deaths unrelated to ALS (Scott et al. 2008).”
Background
Research works printed but not linked: 3
- National Academies of Sciences, Engineering, and Medicine (2015) Reproducibility issues in research with animals and animal models: workshop in Brief. The National Academies Press, Washington, DC, 1–8. ISBN 978-0-309-38017-1
- Tabrizi SJ, Cleeter MW, Xuereb J, Taanman JW, Cooper JM, Schapira AH (1999) Biochemical abnormalities and excitotoxicity in Huntington’s disease brain. Ann Neurol 45(1):25–32 · doi:10.1002/1531-8249(199901)45:1<25::aid-art6>3.0.co;2-e
- Yang L, Calingasan NY, Wille EJ, Cormier K, Smith K, Ferrante RJ, Beal MF (2009) Combination therapy with coenzyme Q10 and creatine produces additive neuroprotective effects in models of Parkinson’s and Huntington’s diseases. J Neurochem 109(5):1427–1439. doi: 10.1111/j.1471-4159.2009.06074.x · DOI · Paper page
Cited by
Kreider, R. B., Kalman, D. S., Antonio, J., Ziegenfuss, T. N., Wildman, R., Collins, R., Candow, D. G., Kleiner, S. M., Almada, A. L., & Lopez, H. L. (2017) · Journal of the International Society of Sports Nutrition · doi:10.1186/s12970-017-0173-z · Cited by 1,057
“Moreover, long-term, high dose ingestion of creatine (up to 30 g/d for up to 5 years) in patient populations has not been associated with an increased incidence of renal dysfunction [23, 155, 156, 172].”
BackgroundInfluentialCreatine in health and disease
Kreider, R. B., & Stout, J. R. (2021) · Nutrients · doi:10.3390/nu13020447 · Cited by 227
“However, a large multi-site clinical trial conducted by Bender and coworkers [51] on PD, HD, and ALS patients did not find promising results.”
BackgroundMetabolic Basis of Creatine in Health and Disease: A Bioinformatics-Assisted Review
Bonilla, D. A., Kreider, R. B., Stout, J. R., Forero, D. A., Kerksick, C. M., Roberts, M. D., & Rawson, E. S. (2021) · Nutrients · doi:10.3390/nu13041238 · Cited by 223
“Brain BB-CK uMtCK Supports brain cells energy production and buffers ATP and ion pumping during electrical activity in neurons [50].”
BackgroundDolan, E., Gualano, B., & Rawson, E. S. (2019) · European Journal of Sport Science · doi:10.1080/17461391.2018.1500644 · Cited by 171
“…2017; Devries & Phillips, 2014; Gualano, Rawson, Candow, & Chilibeck, 2016; Rawson & Venezia, 2011), and patient populations (reviewed in Bender & Klopstock, 2016; Gualano, Roschel, Lancha, Brightbill, & Rawson, 2012) have also been thoroughly researched and © 2018 European College of Sport…”
Effects of creatine supplementation on brain function and health
Forbes, S. C., Cordingley, D. M., Cornish, S. M., Gualano, B., Roschel, H., Ostojic, S. M., Rawson, E. S., Roy, B. D., Prokopidis, K., Giannos, P., et al. (2022) · Nutrients · doi:10.3390/nu14050921 · Cited by 145
Metadata
- Authors
- Bender, A., & Klopstock, T.
- Affiliations
- Therapiezentrum Burgau (DE)
- German Center for Neurodegenerative Diseases (DE)
- Corresponding author
- Bender, Andreas
- Venue
- Amino Acids
- Published
- 2016-01-09
- Volume
- 48
- Issue
- 8
- Pages
- 1929-1940
- ISSN
- 0939-4451 (ISSN-L)
- 1438-2199
- OpenAlex
- W2231841779
- Cited by
- 96
- References
- 73
- Citations by year
- 2026: 8 · 2025: 10 · 2024: 7 · 2023: 9 · 2022: 9 · 2021: 9 · 2020: 12 · 2019: 12 · 2018: 6 · 2017: 7 · 2016: 7
- FWCI
- 1.48
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Amino Acids (publishedVersion)
- PubMed (publishedVersion)
- DZNE Pub (submittedVersion)
- OPUS (Augsburg University) (submittedVersion)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Life Sciences › Neuroscience › Neurology › Neuroprotection in Cerebral Ischemia
- Health Sciences › Medicine › Physiology (medical) › Biochemical effects in animals
- Keywords
- creatine supplementation, neuroprotection, neurodegenerative diseases, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, oxidative stress, glutamate excitotoxicity, apoptosis, brain atrophy, clinical trial results, energy homeostasis
- MeSH terms
- Animals, Creatine, Disease Models, Animal, Dose-Response Relationship, Drug, Humans, Randomized Controlled Trials as Topic, Neuroprotective Agents, Neurodegenerative Diseases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Creatine for neuroprotection in neurodegenerative disease: end of story? https://app.cochat.ai/papers/10.1007/s00726-015-2165-0
- The paper
- Bender, A., & Klopstock, T. (2016). Creatine for neuroprotection in neurodegenerative disease: end of story? Amino Acids. https://doi.org/10.1007/s00726-015-2165-0
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.